Researcher, Masaryk University, Brno, Czechia

Project: “Biomarker(s) predicting bevacizumab treatment response and alternative therapeutic targets in metastatic colorectal cancer”

Background:
The angiogenesis inhibitor Bevacizumab (BEV) is part of the first-line treatment strategy for metastatic colorectal cancer (mCRC), but half of the patients respond poorly to BEV due to intrinsic or acquires resistance.
With a multi-omics approach Pavla and her coowrkers aim to identify reliable biomarkers to predict a patient’s response to sepcific drugs.

canSERV services:
To identify reliable biomarkers that help to predict how patients respond to BVE, integrating various levels of -omics data, like genomics, proteomics and transcriptomics is needed.
canSERV gives Pavla fre–of-charge access to a large set (more than 1,000) suitable biobank samples and high-quality omics -services. The resulting dataset will be analysed using AI-support.

Societal Impact:
Biomarkers can help to predict a patient’s response to a specific treatment. Finding the right one can accelerate the treatment significantly – saveing time, costs and lives.